Loading
A PD-1 antibody plus an oral anti-VEGF pill beat sorafenib on survival, one of the largest benefits seen in liver cancer.
CARES-310, trial NCT03764293 sponsored by Jiangsu Hengrui and Elevar and reported in 2023, showed that the PD-1 antibody camrelizumab plus the oral anti-VEGF drug rivoceranib beat sorafenib on survival in first-line unresectable hepatocellular carcinoma, one of the largest benefits seen in the disease. It randomised 543 patients in a global trial with about eighty percent Asian enrolment, met both primary endpoints of overall and progression-free survival and produced a much higher response rate. OnCo links it to hepatocellular carcinoma, the camrelizumab plus rivoceranib record, rivoceranib, Jiangsu Hengrui and Shukui Qin. The combination is approved in China but has received three FDA complete response letters over manufacturing, so whether it reaches Western patients is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
543 enrolled.
Shares Rivoceranib (apatinib), Jiangsu Hengrui Pharmaceuticals, Anti-angiogenic therapy, Hepatocellular carcinoma.
Shares Rivoceranib (apatinib), Jiangsu Hengrui Pharmaceuticals, Anti-angiogenic therapy, Hepatocellular carcinoma.
Shares Rivoceranib (apatinib), Jiangsu Hengrui Pharmaceuticals, Anti-angiogenic therapy, Immune checkpoint inhibitors.
Shares Rivoceranib (apatinib), Jiangsu Hengrui Pharmaceuticals, Anti-angiogenic therapy, Immune checkpoint inhibitors.
Shares Rivoceranib (apatinib), Jiangsu Hengrui Pharmaceuticals.
Shares Shukui Qin, Anti-angiogenic therapy, Hepatocellular carcinoma.
Shares Shukui Qin, Hepatocellular carcinoma.
Shares Jiangsu Hengrui Pharmaceuticals, Anti-angiogenic therapy, Immune checkpoint inhibitors.